Author:
O'Donnell Elizabeth,Mo Clifton,Yee Andrew J,Nadeem Omar,Laubach Jacob,Rosenblatt Jacalyn,Munshi Nikhil,Midha Shonali,Cirstea Diana,Chrysafi Pavlina,Horick Nora,Richardson Paul G,Raje Noopur
Funder
Adaptive Biotechnologies Corp
Amgen Inc
Sanofi US
Reference32 articles.
1. Cancer statistics, 2022;Siegel;CA Cancer J Clin,2022
2. NCCN guidelines insights: multiple myeloma, version 3.2022;Callander;J Natl Compr Canc Netw,2022
3. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial;Voorhees;Blood,2020
4. Therapeutic opportunities with pharmacological inhibition of CD38 with isatuximab;Martin;Cells,2019
5. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study;Attal;Lancet,2019
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献